Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients.

Antimicrobial agents and chemotherapy - 1 Mar 2012

Troke Philip J F, Lewis Marilyn, Simpson Paul, Gore Katrina, Hammond Jennifer, Craig Charles, Westby Mike

Abstract excerpt

Filibuvir (PF-00868554) is an investigational nonnucleoside inhibitor of the hepatitis C virus (HCV) nonstructural 5B (NS5B) RNA-dependent RNA polymerase currently in development for treating chronic HCV infection. The aim of this study was to characterize the selection of filibuvir-resistant var...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis C, Chronic
Share to Inhibitory Concentration 50
Share to Methionine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pyrones

Share to Replicon

Share to RNA-Dependent RNA Polymerase

Share to Triazoles

Share to Viral Nonstructural Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 22203605
DOI: 10.1128/AAC.05611-11
PMCID: PMC3294886

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22203605-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients.PMID 22203605Read ↗

Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients.Semantic proximity Read ↗

Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052.Semantic proximity Read ↗

Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.Semantic proximity Read ↗

Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance.Semantic proximity Read ↗

Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay.Semantic proximity Read ↗

Biochemical study of the comparative inhibition of hepatitis C virus RNA polymerase by VX-222 and filibuvir.Semantic proximity Read ↗

Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.Semantic proximity Read ↗

Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5A.Semantic proximity Read ↗

Mutations Identified in the Hepatitis C Virus (HCV) Polymerase of Patients with Chronic HCV Treated with Ribavirin Cause Resistance and Affect Viral Replication Fidelity.Semantic proximity Read ↗

In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor.Semantic proximity Read ↗

Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations.Semantic proximity Read ↗

Preclinical Characterization and In Vivo Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.